Chugai Pharma Manufacturing Co., Ltd. is commissioned to manufacture pharmaceuticals.
Quote | Chugai Pharmaceuticals Co. Ltd. ADR (OTCMKTS:CHGCY)
Last: | $16.03 |
---|---|
Change Percent: | 4.82% |
Open: | $15.9801 |
Close: | $16.03 |
High: | $17 |
Low: | $15.79 |
Volume: | 183,236 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Chugai Pharmaceuticals Co. Ltd. ADR (OTCMKTS:CHGCY)
2024-04-24 23:40:02 ET Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Conference Call April 24, 2024 5:00 AM ET Company Participants Kae Miyata - Head of Corporate Communications Osamu Okuda - President and Chief Executive Officer Tsukasa Kusano - Execu...
2024-03-21 07:00:09 ET More on Argenx SE argenx SE (ARGX) Q4 2023 Earnings Call Transcript argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion Argenx SE GAAP EPS of -$1.68 misses by $0.30, revenue of $374M beats by $10.28M ...
Message Board Posts | Chugai Pharmaceuticals Co. Ltd. ADR (OTCMKTS:CHGCY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Chugai Pharmaceuticals Co. Ltd. ADR Company Name:
CHGCY Stock Symbol:
OTCMKTS Market:
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...
Grandsouth Bancorporation (GRRB) is expected to report for quarter end 2023-09-30 Cadence Bank (CADE) is expected to report $0.56 for Q3 2023 Enterprise Financial Services Corporation (EFSC) is expected to report $1.24 for Q3 2023 Blackhawk Bancorp Inc. (BHWB) is expected to report fo...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...